Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CPT1A | P50416 | 1/20 | 0.31 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25263865 | 0.72 | — | — | |
| SCHEMBL25290141 | 0.69 | CPT2 (0.48) | MEN1KMT2AHTTLMNACPT1A | |
| SCHEMBL30488782 | 0.69 | CPT2 (0.48) | MEN1KMT2AHTTLMNACPT1A | |
| SCHEMBL23149068 | 0.64 | GRM5 (0.45) | NPSR1TP53SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL6980247 | 0.64 | ALDH1A1 (0.40) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1740290 | 0.61 | OPRM1 (0.47) | MEN1KMT2AALDH1A1OPRM1OPRD1 | |
| SCHEMBL6774667 | 0.61 | OPRM1 (0.50) | ACHEALDH1A1OPRM1OPRD1OPRK1 | |
| SCHEMBL1603117 | 0.60 | OPRD1 (0.48) | MEN1KMT2AALDH1A1OPRM1OPRD1 | |
| SCHEMBL4956140 | 0.60 | ALDH1A1 (0.38) | NPSR1MEN1KMT2AHTTACHE | |
| SCHEMBL48800 | 0.59 | OPRM1 (0.48) | MEN1KMT2AALDH1A1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | NPSR1 2057/4885MEN1 1044/4885TP53 2285/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | NPSR1 2057/4885MEN1 1044/4885TP53 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.